tiprankstipranks
Intra-Cellular reports Q4 EPS (45c), consensus (59c)
The Fly

Intra-Cellular reports Q4 EPS (45c), consensus (59c)

Reports Q4 revenue $87.869M, consensus $86.97M. "The robust growth of CAPLYTA in 2022 marked an extraordinary year for our company. During the year we launched our new bipolar depression indication for CAPLYTA and made considerable progress in advancing our late and early-stage clinical programs," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. "I am very proud of our accomplishments and the strong foundation we have built. We expect 2023 to be another year of significant growth for CAPLYTA and the company."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ITCI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles